Equity Financing

Curbline Properties Corp. has priced an underwritten public offering of common stock, aiming to raise approximately $204 million in gross proceeds through forward sale agreements. The transaction, managed by Morgan Stanley and BofA Securities, is expected to close on February 12, 2026. The company will physically settle the agreements within approximately 18 months, using net proceeds for general corporate purposes, including acquisitions and working capital. Underwriters have a 30-day option to purchase additional shares.

Revelation Biosciences is raising approximately $11 million by exercising outstanding warrants at $0.86 per share. This move also involves issuing new warrants for an additional 26,130,000 shares, contingent on stockholder approval. The capital will support the company’s clinical-stage life sciences operations. This financing strategy, while common, may lead to shareholder dilution. The market’s reaction historically has been mixed to such equity-linked financing.

Foghorn Therapeutics secured $50 million in equity financing, extending its operational runway to mid-2028. This capital infusion will support the advancement of its oncology pipeline, including its lead program FHD-909, an oral SMARCA2 inhibitor for NSCLC, and novel degrader programs targeting CBP, EP300, and ARID1B. The financing, which includes common shares and warrants, was led by prominent biotech investors and signals strong confidence in Foghorn’s Gene Traffic Control® platform and innovative cancer therapies.

Onco‑Innovations announced it has hired a U.S. investment bank to advise on a possible Nasdaq cross‑listing and assess a concurrent equity financing. The advisory will evaluate listing requirements, regulatory and governance issues, and capital‑raising strategies. While the engagement signals interest in U.S. market access and additional capital, the company cautions that neither a listing nor financing is guaranteed and details remain under discussion.

SMX (NASDAQ: SMX) unveiled a molecular‑level identity system that embeds traceability into minerals, surviving smelting, blending, alloying and recycling. Pilot projects with Goldstrom, trueGold and CARTIF demonstrated verification for gold and rare‑earths. The company secured a $111.5 million equity purchase agreement to scale global deployment, aiming to enable verified materials to command premiums, expedite customs clearance and lower regulatory risk. Success hinges on rapid industry adoption; sluggish uptake could limit impact and keep unverified materials discounted.

Ameerex Corporation (OTC:HIRU) enters the U.S. energy market with a 40% stake in Falcon Caddo Venture, focusing on the Rasberry Unit in Texas, estimated to hold 24 million BOE. Production is projected to rise from 800 to 5,000 BOPD by mid-2026 through well redevelopments and enhanced recovery techniques. The venture is equity-financed by Qatari shareholders, avoiding debt. Ameerex is also pursuing a partnership for Canadian assets producing over 5,000 BOPD, aiming to expand its North American presence.

VERSES AI Inc. (OTCQB: VRSSD) priced a public offering of 1,007,764 units at US$6.946 each, aiming for gross proceeds of approximately $7 million. Each unit includes one Class A subordinate voting share and one-half warrant. Full warrants are exercisable at US$8.409 per share for 36 months. Proceeds will support the company’s balance sheet, research & development initiatives, and operational needs. The offering is led by agents A.G.P. Canada Investments ULC and U.S. affiliate A.G.P./Alliance Global Partners.